@AchimKaasch about to present SABATO results at #ECCMID2022!
SABATO has been going on for quite a while now!
Question: is switching to oral therapy for low risk SAB possible?
Low risk: negative follow-up BC, no mestatistic infection, intravascular catheters removed, no prosthetic vascular material, not immunosuppressed
Benefits and risks:
Design:
Study meds:
Reasonable choices, but noting that trimethoprim-sulfa inferior to vanc in Paul et al study for MRSA.
CONSORT diagram:
Ended up with smallish numbers still - 108 in oral and 105 in IV arms.
Baseline characteristics:
Only 5% MRSA. Line related infections about 60%.
Results:
No difference between treatment arms.
Certainly no difference in per protocol populations which the presentation focussed on.
Wasn't clear in presentation what the pre-defined non-inferiority margin was. If 5% then in the ITT may not have been NI.
Have looked at the trial protocol. The NI margin was intially 5% but then in the updated protocol increased to 10%. So looks like it meets the NI margin of 10% in the ITT for the primary outcome of SAB related complication in 90d: 0.007 (-0.078 to 0.091).
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.